Get Our Latest Stock Report on FRX Fennec Pharmaceuticals Trading Down 1.5 % Shares of FRX stock opened at C$9.12 on Wednesday. The company has a debt-to-equity ratio of -620.83, a quick ratio of ...

Telos Co. (NASDAQ:TLS – Free Report) – Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Telos in a report issued on Monday, March 10th. Wedbush ...

Richards opened up in an interview with "Impact x Nightline." Denise Richards is opening up about what it's like raising her daughter Eloise, who was born with a rare disorder. "My mom has always ...

Wedbush upgraded National CineMedia (NCMI) to Outperform from Neutral with a $7.50 price target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...

Wedbush also issued estimates for Taiwan Semiconductor Manufacturing’s Q2 2025 earnings at $2.14 EPS, Q3 2025 earnings at $2.33 EPS, Q4 2025 earnings at $2.65 EPS, FY2025 earnings at $9.12 EPS ...

Wedbush currently has a “Outperform” rating and a $57.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

Shares of NASDAQ RMBL opened at $3.54 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.29 and a debt-to-equity ratio of 2.52. The firm has a 50-day moving average of $4.28 ...

Wedbush downgraded Sutro Biopharma (STRO) to Neutral from Outperform with a price target of $2, down from $8. The company announced a reprioritization of its portfolio, which includes the de ...

Getty Images (NYSE:GETY – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Thursday,RTT News reports.

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Marketbeat reports.